Hospital transfusion service operations during the SARS-CoV-2 pandemic: Lessons learned from the AABB hospital survey in preparation for the next infectious disease outbreak

Srijana Rajbhandary1 | Aaron Shmookler2 | Claudia S. Cohn3 | Eduardo Nunes1 | Matthew S. Karafin4 | James Stubbs5 | Monica B. Pagano6

1AABB, Research, Bethesda, Maryland, USA
2WVU, Pathology, Anatomy and Laboratory Medicine, Morgantown, West Virginia, USA
3Lab Medicine and Pathology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA
4University of North Carolina System, Chapel Hill, North Carolina, USA
5Mayo Clinic Rochester, Transfusion Medicine, Rochester, Minnesota, USA
6Department of Laboratory Medicine, The University of Washington, Seattle, Washington, USA

Correspondence
Monica B. Pagano, Department of Laboratory Medicine, The University of Washington, 1959 Pacific Ave NE, Seattle, WA 98115, USA.
Email: monibea@uw.edu

Abstract
Background: The SARS-CoV-2 pandemic disrupted hospital operations, affected the blood supply, and challenged the health care system to develop new therapeutic options, including convalescent plasma (CCP). The aim of this study is to describe and analyze blood supply fluctuations and the use of convalescent plasma in 2020.

Methods: AABB distributed a weekly and biweekly questionnaire through email to hospital-based members (HBM).

Results: The survey was sent to 887 HBM with 479 unique respondents, most of the hospitals served pediatric and adult patients, and all states of the country participated, except Idaho and Vermont. Fifty four percent of HBM reported increased wastage in the early phase of the pandemic (May), which decreased to 4% by the end of June and throughout the rest of the year. The majority of HBM reported receiving alerts from their blood suppliers reporting blood shortages throughout the year. During March and April, only 12% of HBM were performing elective surgical procedures. The top reasons to delay procedures were: bed availability (28%); COVID-19 caseload (23%); and blood availability (19%). By mid-April, 42% HBM had transfused CCP and reported >24 h delay in getting the units; the vast majority obtained CCP using the Expanded Access Protocol, and later, the Emergency Use Authorization. HBM consistently prioritized the most severe patients to receive CCP, but the proportion of severely ill recipients fell from 52% to 37% between May and October, with an increase from 5% to 21% of HBM providing CCP transfusion early in the course of the disease.

Discussion: Blood utilization and availability fluctuated during the pandemic. The fluctuations appeared to be related to the number of COVID-19 in the community. The use and regulatory landscape of CCP rapidly evolved over the first 8 months of the pandemic.

Keywords
blood supply, blood transfusions, hospital operations, pandemic, transfusion services
1 | INTRODUCTION

On January 9, 2020, the World Health Organization (WHO) relayed that at least 59 people in Wuhan, China were infected by a novel and highly infectious coronavirus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).\(^1\) Since that time, there have been over 125 million cases and nearly 3 million deaths worldwide due to COVID-19, the clinical manifestation of SARS-CoV-2.\(^2\) Clearly, the COVID-19 pandemic has exerted a profound effect on healthcare delivery around the world, including the prospect of ever-increasing challenges to the adequacy and safety of the blood supply and to the availability of traditional and new transfusion medicine therapies. The field of Blood Banking/Transfusion Medicine (BB/TM) had an obligation to rapidly and successfully respond to these challenges in order to maintain effective support of healthcare delivery during the pandemic. An early signal of the effect of COVID-19 on the blood supply and transfusion services was provided in a report covering a two-week period in Washington state in early 2020.\(^3\) The precipitous drop in blood collections and change in hospital operations created a state of uncertainty about the adequacy of the blood supply and prospective transfusion needs. What happened in Washington State foreshadowed the effects of COVID-19 on the blood supply and transfusion practices for the rest of the country shortly thereafter. By March 16, 2020, the American Red Cross reported that about 2700 blood drives had been canceled in the U.S., and this represented a decrease of approximately 86,000 blood donations (Pampee P. Young, M.D., Ph.D., e-mail communication, March 2020). On March 20, 2020, the WHO published an interim guidance on the management of the blood supply in response to the COVID-19 pandemic.\(^4\) The WHO emphasized the potential for reduced blood donation and a significant harmful impact on the supply of blood and blood components. Therefore, the WHO recommended that blood services move quickly take steps to assess, plan, and implement mitigation strategies to address these potential threats. In addition, the WHO suggested that convalescent plasma might be useful as a COVID-19 treatment. On May 28, 2020, the AABB, America’s Blood Centers and the American Red Cross issued a joint statement regarding the status of the nation’s blood supply.\(^5\) It was noted that during March, the blood supply decreased to a critically low level. Public statements encouraging blood donation resulted in a strong response with replenishment of the blood supply. At the time of the joint statement, however, blood inventory levels throughout the country were dropping to their lowest levels since the early stages of the pandemic. Maintenance of the blood supply was challenging due to the cancelation of blood drives because many businesses, schools, and community organizations were closed. This joint statement urged individuals to schedule and donate blood at their local blood centers.

In order to understand the impact of the COVID-19 pandemic on BB/TM-related operations and practices, including but not limited to the collection and transfusion of CCP, AABB developed and distributed a multiweek survey about these issues to its hospital-based members (HBM). Herein we present the major findings from this survey.

2 | METHODS

A working group of AABB members was formed to develop the survey questionnaire, including three staff members from the Division of Science and Practice (SR, EN, and CSC) and the chair of the Clinical Transfusion Medicine Committee (MBP). The aim was to query AABB HBM for information regarding the impact of the COVID-19 pandemic on hospital transfusion service operations. The survey questionnaire was distributed by email and included relevant/current issues such as inventory management, transfusion practices, and the acquisition and utilization of CCP. Through June 1, 2020 only Medical Directors (MDs) were invited to participate, thereafter MDs and accreditation contacts from all AABB accredited hospitals were invited. Duplicate responses were identified and removed including only the response from the highest rank (medical director, laboratory director/manager, quality director, laboratory staff) using a facility identification number unique to each AABB hospital. The first survey was released on March 23, 2020. Thereafter, the survey was released Mondays weekly through the week of August 17, 2020. A summary of the results for the first 4 weeks is published.\(^6\) Starting the week of August 31, 2020, the survey was released Mondays on a bi-weekly basis until December 14, 2020. Questions were reviewed and evaluated by the working group every survey week and modifications were made based on epidemiological changes, number of COVID-19 cases, introduction of new treatments, regulatory updates, as well as feedback received from survey respondents. The questions were predominantly objective and rank-order with less than 10% open-ended so that the survey could be completed in about 5 min (see Table S1 for questions included in the questionnaire).

Reports from the survey were released to AABB membership and published on the AABB website by Friday
afternoon of each survey week. Descriptive statistics including frequencies, percentages, and response ratios (for multi-select questions) were included in these survey reports. Survey reports also included US maps to describe the distribution, demand, and utilization of CCP units. Analyses were conducted using SAS 9.4, JMP 15, and Excel. Select survey reports are available for members on the AABB website (https://www.aabb.org/news-resources/resources/hemovigilance/aabb-surveys-and-reports).

3 | RESULTS

3.1 | Demographics

The survey was sent to 887 HBM with 479 unique respondents participating at least once during the survey period. The respondents represented Adult, Pediatric, and Pediatric and Adult institution types, and all states of the country except Idaho and Vermont. Hospitals serving both the Pediatric and Adult populations represented the most common reporting institution type (52.5%, 223/425), and California was the most well-represented state of the country (313 unique respondents in over 30 surveys). Survey responses generally correlated with population density, as does blood transfusion generally.7 On average, each respondent participated in the ongoing survey an average of 8.6 times (SD 8.4). Lastly, participation in this survey was greatest during week of June 8, 2020 (236 unique respondents) and lowest during Week of June 1, 2020 (95 unique respondents).

3.2 | COVID-19s impact on blood inventory

The number of COVID-19 cases in the country increased throughout 2020, with at least two prominent surges, the first in the beginning of summer (June–July) and the second beginning at the end of autumn (November–December). Fifty four percent (54/100) of HBM reported increased wastage during the first week of May, which decreased to 4.5% (7/157) by the end of June and throughout the rest of the year (Figure 1). More than half of HBM (54.8%, 472/861) also reported receiving alerts from their blood suppliers regarding challenges in filling blood orders in particular during June and throughout the first week of July, and then from September to December.

Throughout the pandemic red blood cells units (RBC), especially O Rh positive and O Rh negative, were in shortest supply, followed by platelets, plasma, and cryoprecipitate (Figure 2). Beginning in late September, at least 45% (33/74) of HBM reported an abrupt increase in the shortage of cryoprecipitate and a concomitant increase in blood supplier notification of this shortage.

![Graph showing inventory challenges for transfusion services](image-url)
HBM adapted their practice habits in response to blood shortages. On average, 45% (215/478) of HBM lowered their RBC transfusion hemoglobin threshold to 7 g/dL and implemented prospective auditing of orders for RBC and for platelets, and 12.7% (59/474) of HBM lowered their RBC transfusion thresholds below 7 g/dL.

3.3 COVID-19’s impact on elective surgical procedures

Between March 23rd and April 13th, an average of 12% (44/348) of HBM reported that their respective institution continued to perform elective surgical procedures (ESP), with 26% (91/346) reporting increased wastage secondary to canceled procedures (data previously published). At least 75% (79/105) of HBM consistently reported the resumption of some ESP beginning in mid-May, which increased to 95% (130/137) by mid-August. Despite the continuation or resumption of ESP, 3.2% (40/1264) of HBM consistently reported that ESP were being postponed due to concerns for a second wave of COVID-19 cases beginning in late June. In order of descending frequency, the limitations to resuming ESP included availability of intensive care unit beds (28%, 1344/4781), hospital
COVID-19 case load (23%, 1080/4781), blood availability (19%, 911/4781), personal protective equipment (17%, 815/4781), testing capacity (11%, 508/4781), and others (3% 123/4781). The response distribution of these different options did not change over the time this question was offered.

FIGURE 3 Percentage of HBM reporting the transfusion of CCP and delays in obtaining convalescent plasma

TABLE 1 Mechanisms to obtain COVID-19 convalescent plasma

| Responses from April 20 through June 22 | Average | n  | Total hospitals that transfused CCP |
|----------------------------------------|---------|----|-----------------------------------|
| Hospital protocol (including clinical trials) | 10.0% | 93 | 932 |
| Mayo Clinic Expanded Access Protocol | 86.2% | 803 | 932 |
| Emergency Investigational New Drug (eIND) | 23.9% | 223 | 932 |

| Responses from June 29 through July 13 |
|---------------------------------------|
| Clinical trials | 35.3% | 129 | 365 |
| Mayo Clinic Expanded Access Protocol | 83.8% | 306 | 365 |
| Emergency Investigational New Drug (eIND) | 39.7% | 145 | 365 |

| Responses from August 31* |
|--------------------------|
| Clinical trials | 16.9% | 24 | 142 |
| Emergency Use Authorization (EUA) | 66.9% | 95 | 142 |
| Modified investigational use | 13.4% | 19 | 142 |

| Responses from September 14 through October 12 |
|-----------------------------------------------|
| Clinical trials | 9.3% | 32 | 344 |
| Emergency Use Authorization (EUA) | 59.6% | 205 | 344 |
| Investigational use (units not labeled) | 38.1% | 131 | 344 |

| Responses from October 26 through December 14 |
|-----------------------------------------------|
| Clinical trials | 13.0% | 51 | 391 |
| Other including Emergency Use Authorization (EUA) | 93.6% | 366 | 391 |

*Single selection question in the week of August 31.
As COVID-19 cases were rising, HBM reported increased CCP transfusions and also initial delays in obtaining CCP. By late April, 51% (52/102) of HBM reported transfusing at least one unit CCP, but 42% (43/102) also experienced a delay of at least 24 h in obtaining CCP (Figure 3). Greater than 75% (84/106) HBM were consistently transfusing CCP as early as mid-May, plateauing at over 90% (110/122) as early as late October, and with as little as 5% (7/112) reporting delays by mid-October. The vast majority of HBM reported obtaining CCP using the Expanded Access Protocol, and later, the Emergency Use Authorization pathway (Table 1).

Over the course of 20 surveys (from the week of May 4th through October 12th), HBM consistently prioritized the following patients for CCP transfusion: 46.9% (1209/2577) used CCP for severely ill patients; 21.2% (546/2577) used CCP as the last resort if all other treatment options failed to demonstrate clinical improvement; and 13.4% (345/2577) used CCP for moderately ill patients (Figure 4). Timing of diagnosis or admission was considered by 12.9% (332/2577) of HBM. Only 6% (145/2577) of HBM reported using CCP for mildly ill patients. However, these priorities changed over time. Figure 4 shows a modest but steady decline in CCP prioritized for severely ill patients [from 52% (47/90) to 37% (39/104)] and a converse increase in the proportion of patients who were given CCP early, either relative to the date of SARS-CoV-2 infection or hospital admission [from 5% (5/90) to 21% (22/104)].

The early stages of the pandemic were marked by a paradoxical combination of blood wastage and blood shortages.8–10 The majority of HBM responded by lowering their RBC transfusion hemoglobin threshold to 7 g/dL for most patient populations. This is a surprising observation as current AABB and other society guidelines recommend a restrictive transfusion threshold of 7 g/dL for most patients.11 It is encouraging, though, that many respondents implemented other methods, such as prospectively auditing RBC and platelet orders. Prospective auditing, which can be performed by laboratory personnel such as pathology residents and medical laboratory technologists, reduces unnecessary transfusions, and can be a component of a successful patient blood management program.12–14

On the other hand, there was an increase in blood wastage due to the cancelation of elective surgeries. The American College of Surgeons developed the Elective Surgery Acuity Scale to assist hospitals and surgery centers in triaging non-emergent surgical procedures during the COVID-19 pandemic.15 Based on this scale, arguably most,
if not all, surgical procedures associated with the highest risk of RBC transfusion—and which account for over 50% of surgical patients exposed to RBC transfusion—should not have been postponed. This suggests a significant portion of blood utilization is attributed to elective surgeries, which is somewhat unexpected given that transfusion requirements are higher in non-ESP compared to ESP.18,19 Despite the implementation of a maximal surgical blood order schedule to improve the efficiency of blood ordering practices for ESP,20 crossmatch-to-transfusion ratios remain high and/or blood is underutilized.21,22 Respondents were not asked to identify surgeries that were impacted explicitly. Yet, this finding could provide insight into the evaluation and treatment of preoperative anemia (another patient blood management program component23), the benefits of which might include decreased blood transfusions, not to mention improved outcomes and shorter length of hospital stay.24–28 Notably, a recent randomized controlled trial showed that patients receiving iron supplementation were not transfused less blood compared to patients who did not receive iron up to 42 days before major abdominal surgery.29

The counterbalance between blood shortage and blood wastage was likely overshadowed by external factors affecting overall hospital utilization. ICU bed availability and COVID-19 caseload, not blood availability, were the most relevant considerations for canceling surgeries; PPE availability was a close fourth. Remarkably, blood supplier notification was closely associated with reduced wastage throughout the course of the pandemic despite the resumption of ESP30–32 and despite the increasing number of COVID-19 cases. Wastage remained at or below 10% even as notifications reached their lowest levels in mid-August, by which time blood suppliers were able to increase their donor pools in response to blood donor eligibility criteria modifications made by the Food and Drug Administration.33

This survey confirmed that the availability of specific blood components did fluctuate, which mirror the findings reported by Barriteau et al.34 Respondents clearly and consistently specify group O RBCs as the most affected blood component. This is likely explained by hospitals focusing care on traumas and other surgical emergencies during the pandemic;35 many of these patients often present initially with no known blood type, thereby requiring the emergency release of group O RBCs. At one large academic medical center, Pagano et al.36 reported lower admission rates and overall blood use due to the postponement of ESP, and an increased proportion of massive transfusion protocol activations compared to the previous 2 years (2019 and 2018). Moreover, patients with severe COVID-19 infections did not appear to have increased transfusion needs,34,37,38 other than convalescent plasma.39–41 Although many of these patients received extracorporeal membrane oxygenation,42 the latest guidelines from the Extracorporeal Life Support Organization do not recommend deviating from usual institutional practices for blood transfusion thresholds,43 which otherwise may be kept low (hemoglobin 7 g/dL) as is the practice in experienced centers.44 Reserve shortages of plasma and its derivative, cryoprecipitate, were observed a few months into the pandemic as blood suppliers concentrated their efforts in manufacturing convalescent plasma.

Initially, respondents reported transfusing convalescent plasma primarily based on disease severity and later based on timing of the disease and based on the safety update regarding the COVID-19 Convalescent Plasma Expanded-Access Program.45 The Program was a collaboration between the American Red Cross and an academic institution, Mayo Clinic, and the results of retrospective analysis led to the Emergency Use Authorization of convalescent plasma.46

The major limitation of this study is that questions were continuously revised and fine-tuned over time. This introduced the risk of bias and precluded accurate and meaningful statistical analyses. The survey was not formally validated for clarity or content, and so errors in question interpretation were possible. Also, most HBM did not respond to the survey every single week, leading to an inability to assess practice changes by individual respondent or institution. The first surveys were submitted to only medical directors, and due to low response rate, starting on week of June 8, two contacts (medical directors and accredited contacts) were invited for each respondent or institution. The survey period, limiting the value of continuing the survey responses did not change over the last weeks of the survey period, limiting the value of continuing the survey. Further, additional practice surveys have been completed in 2021 by other groups, and we look forward to seeing how the results of those surveys add to the findings of our own work.

These limitations aside, the strength of this cross-sectional survey study included the relatively high number of participating respondents, representing both pediatric and adult hospitals from every state in the United States except for Idaho and Vermont. There is clear evidence that HBM made significant practice adjustments in keeping up with the latest research developments. For example, an increasing number of HBM were transfusing CCP early in the disease course in accordance with new findings.47,48
Transfusion medicine and blood banking does not stop during a pandemic, although many aspects of the pandemic directly and indirectly affected the blood industry. The principal lesson learned from this study, which can be applied to the next infectious disease outbreak, is to plan ahead, stay organized, and carry on in maintaining close communication between hospitals and blood suppliers. For every action there is an equal and opposite reaction, none perhaps as great as fallout from a pandemic: social distancing and business closures, not to mention actively ill donors, will lead to blood supply shortages; an anticipated decrease in the volume of ESP will lead to a decrease in blood utilization and subsequent wastage of blood products. By identifying these counterforces early, the supply and demand of blood may be adjusted accordingly to mitigate product wastage without compromising patient care. Furthermore, close communication provides the inspiration for future collaborative studies that can inform the next pandemic, such as prospective studies toward the appropriate marketing and use of convalescent plasma. However, this does not absolve blood banks from revising transfusion practices now in accordance with current evidence-based guidelines and recommendations. Blood banks and their affiliated hospitals always have the opportunity to implement elements of a patient blood management program such as transfusion auditing and preoperative anemia management. This would not only crystallize institutional blood needs but also make vacillations in manufactured blood components potentially more predictable and more manageable.

CONFLICT OF INTEREST
Nothing to disclose.

ORCID
Aaron Shmookler https://orcid.org/0000-0001-7789-7184
Claudia S. Cohn https://orcid.org/0000-0001-9847-0470
James Stubbs https://orcid.org/0000-0002-3270-4913
Monica B. Pagano https://orcid.org/0000-0001-5183-6471

REFERENCES
1. World Health Organization. Listings of WHO’s response to COVID-19. 2020 [cited 2021 Aug 1]. Available from: https://www.who.int/news/item/29-06-2020-covidtimeline.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533–4.
3. Pagano MB, Hess JR, Tsang HC, Staley E, Gernsheimer T, Sen N, et al. Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID-19) pandemic affecting Washington State. Transfusion. 2020;60(5):908–11.
4. World Health Organization. Maintaining a safe and adequate blood supply during the pandemic outbreak of coronavirus disease (COVID-19): interim guidance. Geneva PP—Geneva: World Health Organization; 2020 Available from: https://apps.who.int/iris/handle/10665/331523
5. AABB, America’s Blood Centers, American Red Cross. Joint statement on the nation’s blood supply. 2020 [cited 2021 Aug 3]. Available from: https://www.redcross.org/about-us-news-and-events/press-release/2020/joint-statement-on-the-nations-blood-supply.html.
6. Pagano MB, Rajbhandary S, Nunes E, Cohn CS. Transfusion services operations during the COVID-19 pandemic: results from AABB survey. Transfusion. 2020;60:2760–2.
7. Cobain TJ, Vamvakas EC, Wells A, Titlestad K. A survey of the demographics of blood use. Transfus Med. 2007;17(1):1–15.
8. Stiepan D. Critical blood shortages because of COVID-19. Mayo Clinic News Network. 2020 Mar 16; Available from: https://newsnetwork.mayoclinic.org/discussion/critical-blood-shortages-because-of-covid-19/.
9. Yu A. How COVID-19 led to a blood shortage, and why that’s troubling. WHYY News; 2020.
10. Yazer MH, Jackson B, Pagano M, Rahimi-Levene N, Peer V, Bueno JL, et al. Vox Sanguinis international forum on transfusion services’ response to COVID-19: summary. Vox Sang. 2020;115(6):536–42.
11. Carson JL, Guyatt G, Hedde NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025–35.
12. Madrigal E, Prajapati S, Avadhani V, Annen K, Friedman MT. Adequacy of physician documentation and correlation with assessment of transfusion appropriateness: a follow-up study in the setting of prospective audits and patient blood management. Transfusion. 2017;57(2):367–75.
13. Lin Y, Cserti-Gazdewich C, Lieberman L, Pendergrast J, Rammler W, Skinner I, et al. Improving transfusion practice with guidelines and prospective auditing by medical laboratory technologists. Transfusion. 2016;56:2903–5.
14. Haldiman L, Zia H, Singh G. Improving appropriateness of blood utilization through prospective review of requests for blood products: the role of pathology residents as consultants. Lab Med. 2014;45(3):264–71.
15. American College of Surgeons. COVID-19: guidance for triage of non-emergent surgical procedures. 2020. Available from: https://www.facs.org/covid-19-clinical-guidance/triage.
16. Montroy J, Lavallée LT, Zarychanski R, Fergusson D, Houston B, Cagiannos I, et al. The top 20 surgical procedures associated with the highest risk for blood transfusion. Br J Surg Engl. 2020;107:e642–3.
17. Meredith JW, High KP, Freischlag JA. Preserving elective surgeries in the COVID-19 pandemic and the future. JAMA. 2020;324(17):1725–6.
18. Anis HK, Sodhi N, Coste M, Ehiroubo JO, Newman JM, Garbarino LJ, et al. A comparison of peri-operative outcomes between elective and non-elective total hip arthroplasties. Ann Transl Med. 2019;7(4):78.
19. Sodhi N, Anis HK, Coste M, Ehiorobo JO, Chee A, Freund B, et al. A nationwide analysis of preoperative planning on operative times and postoperative complications in total knee arthroplasty. J Knee Surg. 2019;32(11):1040–5.

20. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on perioperative blood management. Anesthesiology. 2015;122(2):241–75.

21. Lowe E, Quarmby J. Are we cross-matching too much blood for elective open abdominal aortic aneurysm repair? SAGE Open Med. 2017;5:205032116688843.

22. Guzman JPS, Resurrection LL, Gepte MBP. Use of maximum surgical order schedule (MSBOS) among pediatric patients to optimize blood utilization. Ann Pediatr Surg. 2019;15(1):4. https://doi.org/10.1186/s43159-019-0005-9

23. Patient Blood Management Standards Committee. Standards for a patient blood management program. 3rd ed. Bethesda, MD: AABB; 2020.

24. Abdullah HR, Thannachat T, Hao Y, Lim WY, Teo LM, Sim YE. Real-world results of the implementation of preoperative anaemia clinic with intravenous iron therapy for treating iron-deficiency anaemia: a propensity-matched case-control study. Ann Transl Med. 2021;9(1):6.

25. Scrimshire AB, Booth A, Fairhurst C, Kotze A, Reed M, McDaid C. Preoperative iron treatment in anaemic patients undergoing elective total hip or knee arthroplasty: a systematic review and meta-analysis. BMJ Open. 2020;10(10):e036592.

26. Crouch BJ, Gupta R, Christy DM. West Virginia behavioral risk factor surveillance system report 2016. [cited 2020 Jun 22]. Available from: www.wvdhhr.org/bph/hsc.

27. Banerjee S, McCormack S. Intravenous iron preparations for patients undergoing elective surgery: a review of clinical effectiveness, cost-effectiveness, and guidelines. Intravenous iron preparations for patients undergoing elective surgery: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019 [cited 2021 Feb 11]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31487129

28. Munting KE, Klein AA. Optimisation of pre-operative anaemia in patients before elective major surgery – why, who, when and how? Anaesthesia. 2019;74(Suppl 1):49–57.

29. Richards T, Baikady RR, Clevenger B, Butcher A, Abeysiri S, Chau M, et al. Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet (Lond, Engl). 2020;396(10259):1353–61.

30. Serrano OK, Orlando R, Papasavas P, McClure MH, Kumar A, Steinberg AC, et al. Getting back to work: a framework and pivot plan to resume elective surgery and procedures after COVID-19. Surg Open Sci. 2021;4:12–8.

31. Wohler AD, Kneisl JS, Macknet DM, Hysong AA, Kaney K, Moroney S, et al. Surgical re-entry strategy following COVID-19 pandemic: a tiered and balanced approach. Med Care. 2021;59(3):220–7.

32. Pirracchio R, Mavrothalassitis O, Mathis M, Kheterpal S, Legrand M. Response of US hospitals to elective surgical cases in the COVID-19 pandemic. Br J Anaesth. 2021;126:e46–8.

33. Food and Drug Administration. Coronavirus (COVID-19) update: FDA provides updated guidance to address the urgent need for blood during the pandemic. 2020. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-provides-updated-guidance-address-urgent-need-blood-during-pandemic

34. Barritteau CM, Bochey P, Lindholm PF, Hartman K, Sumugod R, Ramsey G. Blood transfusion utilization in hospitalized COVID-19 patients. Transfusion. 2020;60(9):1919–23.

35. Bugaev N, Hojman HM, Breeze JL, Nasraway SA, Arabian SS, Holewinski S, et al. Acute care surgery service is essential during a nonsurgical catastrophic event, the COVID-19 pandemic. Am Surg. 2020;86(12):1629–35.

36. Pagano MB, Cataife G, Fertrin KY, Gernsheimer T, Hess JR, Staley E, et al. Blood use and transfusion needs at a large health care system in Washington state during the SARS-CoV-2 pandemic. Transfusion. 2020;60(12):2859–66.

37. Murphy C, Fontaine M, Luethy P, McGann H, Jackson B. Blood usage at a large academic center in Maryland in relation to the COVID-19 pandemic in 2020. Transfusion. 2021;61(7):2075–81.

38. Stanworth SJ, New HV, Apelseth TO, Cardigan R, Doree C, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol. 2020;7(10):e756–64.

39. Mayo Clinic. Covid-19 convalescent plasma expanded-access program. 2020. Available from: https://www.uscovidplasma.org/.

40. Kracalik I, Mowla S, Katz L, Cumming M, Sapiano MRP, Basavaraju SV. Impact of the early coronavirus disease 2019 pandemic on blood utilization in the United States: a timeseries analysis of data reported to the National Healthcare Safety Network Hemovigilance Module. Transfusion. 2021;61(9):e36–43. https://doi.org/10.1111/trf.16451.

41. DeSimone RA, Costa VA, Kane K, Sepulveda JL, Ellsworth GB, Gulick RM, et al. Blood component utilization in COVID-19 patients in New York City: transfusions do not follow the curve. Transfusion. 2021;61(3):692–8.

42. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8(5):518–26.

43. Badulak J, Antonini MV, Stead CM, Shekerdemian L, Raman L, Paden ML, et al. Extracorporeal membrane oxygenation for COVID-19: updated 2021 guidelines from the extracorporeal life support organization. ASAIO J. 2021;67(5):485–95.

44. Ramanathan K, MacLaren G, Combes A, Brodie D, Shekar K. Blood transfusion strategies and ECMO during the COVID-19 pandemic – authors’ reply. Lancet Respir Med. 2020;8:e41.

45. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888–97.

46. Food and Drug Administration. FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administration's...
fight against pandemic. 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment.

47. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021;384(7):610–8.

48. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG. Am J Pathol. 2021;191(1):90–107.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Rajbhandary S, Shmookler A, Cohn CS, Nunes E, Karafin MS, Stubbs J, et al. Hospital transfusion service operations during the SARS-CoV-2 pandemic: Lessons learned from the AABB hospital survey in preparation for the next infectious disease outbreak. Transfusion. 2021;61:3129–38. https://doi.org/10.1111/trf.16643